NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/21/2025
Back to search
Official data from USPTO
DUOBODY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DUOBODY
ST13
US500000079093886Class
1, 5, 42, 45
Filing
79093886
Registration
4103714
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
03/21/2025
Trademark type
Word
Nice classes
1, 5, 42, 45
Filing date
12/30/2010
Registration date
02/28/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/07/2023
Last transaction
06/05/2024
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DK
Examiner
SMIGA,HOWARD
Law office
L20
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Genmab A/S
Representatives
Max Vern AMSTER, ROTHSTEIN & EBENSTEIN LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biochemicalsmonoclonal antibodies for in vivo or in vitro scientific research and development regarding cancerAIDS (acquired immune deficiency syndrome)other infectious diseasesimmune and autoimmune diseasesinflammatory diseases and cardiovascular diseases
Class 5
Pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancerAIDS (acquired immune deficiency syndrome) and other infectious diseasesimmune and autoimmune diseasesinflammatory diseases and cardiovascular diseases
Class 42
Medical and scientific researchbiological scientific research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for the treatment of cancerAIDS (acquired immune deficiency syndrome) and other infectious diseasesimmune and autoimmune diseasesinflammatory diseases and cardiovascular diseases; chemical analysis; computer programmingprogramming of computers for the collection and processing of medical data in medical scientific researchdevelopment and therapy with monoclonal antibodies
Class 45
Patent exploitationpatent licensing ; licensing of intellectual property in the field of medicine
Publications
History of USPTO decisions and trademark events.
50 publications found
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/05/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/05/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/05/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/15/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/07/2023
71AG
REGISTERED-SEC.71 ACCEPTED
02/07/2023
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
02/06/2023
PR71
POST REGISTRATION ACTION MAILED - SEC.71
08/04/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/02/2022
ES71
TEAS SECTION 71 RECEIVED
02/28/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
02/28/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
01/21/2021
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
09/07/2018
71AG
REGISTERED-SEC.71 ACCEPTED
09/07/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/07/2018
ES71
TEAS SECTION 71 RECEIVED
08/27/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/26/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/08/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/20/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/09/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/09/2017
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/04/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/15/2012
FIMP
FINAL DISPOSITION PROCESSED
10/15/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/28/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
02/28/2012
PUBO
PUBLISHED FOR OPPOSITION
12/13/2011
NPUB
NOTICE OF PUBLICATION
11/23/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/10/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/07/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/07/2011
ALIE
ASSIGNED TO LIE
10/24/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/13/2011
PETG
PETITION TO REVIVE-GRANTED
10/13/2011
PROA
TEAS PETITION TO REVIVE RECEIVED
10/13/2011
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/03/2011
RFNT
REFUSAL PROCESSED BY IB
04/17/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/29/2011
RFRR
REFUSAL PROCESSED BY MPU
03/29/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/29/2011
CNRT
NON-FINAL ACTION WRITTEN
03/28/2011
DOCK
ASSIGNED TO EXAMINER
03/25/2011
MAFR
APPLICATION FILING RECEIPT MAILED
03/22/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/16/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/10/2011
Continuous trademark protection
Get notified about every new filing that threatens DUOBODY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.